Stem definition | Drug id | CAS RN |
---|---|---|
vinca alkaloids | 2827 | 71486-22-1 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 1000 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 11 % | Benet LZ, Broccatelli F, Oprea TI |
BA (Bioavailability) | 27 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 23 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.87 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 26 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 23, 1994 | FDA | PIERRE FABRE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malignant neoplasm progression | 709.74 | 22.19 | 359 | 14148 | 67765 | 50522852 |
Disease progression | 538.52 | 22.19 | 337 | 14170 | 95529 | 50495088 |
Metastases to liver | 401.87 | 22.19 | 167 | 14340 | 19937 | 50570680 |
Metastases to bone | 385.20 | 22.19 | 157 | 14350 | 17838 | 50572779 |
Neutropenia | 375.83 | 22.19 | 322 | 14185 | 147643 | 50442974 |
Palmar-plantar erythrodysaesthesia syndrome | 290.83 | 22.19 | 133 | 14374 | 19965 | 50570652 |
Metastases to lung | 238.63 | 22.19 | 97 | 14410 | 10923 | 50579694 |
Neoplasm progression | 211.17 | 22.19 | 121 | 14386 | 29036 | 50561581 |
Metastases to lymph nodes | 194.90 | 22.19 | 74 | 14433 | 6950 | 50583667 |
Mucosal inflammation | 175.61 | 22.19 | 121 | 14386 | 40021 | 50550596 |
Breast cancer metastatic | 157.47 | 22.19 | 71 | 14436 | 10293 | 50580324 |
Metastases to central nervous system | 151.70 | 22.19 | 71 | 14436 | 11211 | 50579406 |
Neuropathy peripheral | 134.84 | 22.19 | 152 | 14355 | 96605 | 50494012 |
PIK3CA-activated mutation | 116.10 | 22.19 | 30 | 14477 | 780 | 50589837 |
Febrile neutropenia | 108.94 | 22.19 | 137 | 14370 | 97530 | 50493087 |
Pleural effusion | 98.46 | 22.19 | 119 | 14388 | 81335 | 50509282 |
Breast cancer recurrent | 90.98 | 22.19 | 36 | 14471 | 3772 | 50586845 |
Ejection fraction decreased | 88.49 | 22.19 | 59 | 14448 | 18461 | 50572156 |
Haematotoxicity | 85.93 | 22.19 | 43 | 14464 | 7852 | 50582765 |
Osteonecrosis of jaw | 80.56 | 22.19 | 70 | 14437 | 32456 | 50558161 |
Metastases to peritoneum | 79.12 | 22.19 | 30 | 14477 | 2803 | 50587814 |
Tonsillar disorder | 77.40 | 22.19 | 23 | 14484 | 1011 | 50589606 |
Thrombocytopenia | 72.95 | 22.19 | 131 | 14376 | 127542 | 50463075 |
Blood uric acid decreased | 72.77 | 22.19 | 20 | 14487 | 662 | 50589955 |
Eosinophil percentage increased | 66.05 | 22.19 | 20 | 14487 | 938 | 50589679 |
Neurotoxicity | 65.73 | 22.19 | 45 | 14462 | 14695 | 50575922 |
Breast cancer | 64.16 | 22.19 | 70 | 14437 | 42820 | 50547797 |
Metastases to skin | 62.78 | 22.19 | 21 | 14486 | 1362 | 50589255 |
Off label use | 62.62 | 22.19 | 285 | 14222 | 474141 | 50116476 |
Myelosuppression | 62.02 | 22.19 | 42 | 14465 | 13475 | 50577142 |
Polyneuropathy | 61.23 | 22.19 | 40 | 14467 | 12091 | 50578526 |
Ascites | 59.78 | 22.19 | 62 | 14445 | 35799 | 50554818 |
Fall | 59.30 | 22.19 | 12 | 14495 | 334920 | 50255697 |
Nasal disorder | 59.30 | 22.19 | 23 | 14484 | 2285 | 50588332 |
Bone marrow failure | 55.74 | 22.19 | 53 | 14454 | 27571 | 50563046 |
EGFR gene mutation | 54.43 | 22.19 | 13 | 14494 | 242 | 50590375 |
Neutropenic sepsis | 48.89 | 22.19 | 37 | 14470 | 14110 | 50576507 |
Drug hypersensitivity | 48.79 | 22.19 | 7 | 14500 | 251003 | 50339614 |
Death | 47.00 | 22.19 | 201 | 14306 | 325178 | 50265439 |
Osteonecrosis | 43.16 | 22.19 | 42 | 14465 | 22475 | 50568142 |
Decreased appetite | 43.07 | 22.19 | 141 | 14366 | 200782 | 50389835 |
Joint swelling | 42.94 | 22.19 | 9 | 14498 | 245277 | 50345340 |
Tumour marker increased | 42.03 | 22.19 | 21 | 14486 | 3819 | 50586798 |
Vessel puncture site bruise | 40.44 | 22.19 | 11 | 14496 | 350 | 50590267 |
Second primary malignancy | 40.37 | 22.19 | 25 | 14482 | 6889 | 50583728 |
Hepatotoxicity | 39.95 | 22.19 | 44 | 14463 | 27182 | 50563435 |
Leukopenia | 39.42 | 22.19 | 70 | 14437 | 67458 | 50523159 |
Peripheral sensory neuropathy | 38.91 | 22.19 | 24 | 14483 | 6567 | 50584050 |
Lymphangiosis carcinomatosa | 38.28 | 22.19 | 14 | 14493 | 1182 | 50589435 |
Blood creatinine decreased | 36.92 | 22.19 | 21 | 14486 | 4955 | 50585662 |
Therapy partial responder | 36.39 | 22.19 | 23 | 14484 | 6568 | 50584049 |
Gastrointestinal toxicity | 35.40 | 22.19 | 20 | 14487 | 4657 | 50585960 |
Hyperchlorhydria | 34.95 | 22.19 | 14 | 14493 | 1514 | 50589103 |
Superior vena cava syndrome | 34.74 | 22.19 | 11 | 14496 | 599 | 50590018 |
Stomatitis | 34.34 | 22.19 | 84 | 14423 | 101260 | 50489357 |
Injection site extravasation | 33.67 | 22.19 | 23 | 14484 | 7478 | 50583139 |
Mediastinum neoplasm | 33.62 | 22.19 | 7 | 14500 | 67 | 50590550 |
Hypothalamo-pituitary disorder | 33.45 | 22.19 | 11 | 14496 | 676 | 50589941 |
Metastases to chest wall | 33.04 | 22.19 | 10 | 14497 | 468 | 50590149 |
Blood lactate dehydrogenase increased | 32.91 | 22.19 | 34 | 14473 | 19528 | 50571089 |
Cardiotoxicity | 32.62 | 22.19 | 22 | 14485 | 7005 | 50583612 |
Metastases to spine | 32.52 | 22.19 | 16 | 14491 | 2815 | 50587802 |
Transaminases | 32.10 | 22.19 | 7 | 14500 | 85 | 50590532 |
Metastasis | 31.21 | 22.19 | 18 | 14489 | 4357 | 50586260 |
Osteolysis | 31.02 | 22.19 | 15 | 14492 | 2542 | 50588075 |
Diarrhoea | 31.00 | 22.19 | 280 | 14227 | 588196 | 50002421 |
Pituitary tumour | 30.97 | 22.19 | 11 | 14496 | 854 | 50589763 |
Disease recurrence | 30.41 | 22.19 | 33 | 14474 | 20048 | 50570569 |
Skin toxicity | 30.34 | 22.19 | 17 | 14490 | 3896 | 50586721 |
Nausea | 30.05 | 22.19 | 321 | 14186 | 705077 | 49885540 |
Hiccups | 29.90 | 22.19 | 13 | 14494 | 1726 | 50588891 |
Arthralgia | 29.84 | 22.19 | 50 | 14457 | 438652 | 50151965 |
Pruritus | 29.37 | 22.19 | 23 | 14484 | 283545 | 50307072 |
Constipation | 29.30 | 22.19 | 118 | 14389 | 185590 | 50405027 |
Hormone receptor positive breast cancer | 28.66 | 22.19 | 9 | 14498 | 477 | 50590140 |
Folate deficiency | 28.44 | 22.19 | 13 | 14494 | 1942 | 50588675 |
Metastases to meninges | 28.14 | 22.19 | 13 | 14494 | 1989 | 50588628 |
Abdominal discomfort | 27.72 | 22.19 | 16 | 14491 | 231625 | 50358992 |
Maternal exposure during pregnancy | 27.66 | 22.19 | 6 | 14501 | 159772 | 50430845 |
Acquired gene mutation | 27.61 | 22.19 | 10 | 14497 | 821 | 50589796 |
Lymphoedema | 27.48 | 22.19 | 22 | 14485 | 9100 | 50581517 |
Gene mutation | 26.85 | 22.19 | 11 | 14496 | 1260 | 50589357 |
Pancytopenia | 26.72 | 22.19 | 68 | 14439 | 83962 | 50506655 |
Urticaria | 26.63 | 22.19 | 3 | 14504 | 129558 | 50461059 |
Drug ineffective | 26.60 | 22.19 | 133 | 14374 | 819200 | 49771417 |
Metastases to pleura | 26.56 | 22.19 | 11 | 14496 | 1295 | 50589322 |
Sinusitis | 26.47 | 22.19 | 8 | 14499 | 170550 | 50420067 |
Hypertransaminasaemia | 26.14 | 22.19 | 15 | 14492 | 3596 | 50587021 |
Condition aggravated | 26.13 | 22.19 | 28 | 14479 | 297030 | 50293587 |
Vascular device infection | 25.97 | 22.19 | 16 | 14491 | 4368 | 50586249 |
Metastatic neoplasm | 25.60 | 22.19 | 15 | 14492 | 3739 | 50586878 |
Dermatitis exfoliative generalised | 25.38 | 22.19 | 14 | 14493 | 3112 | 50587505 |
Gingival bleeding | 25.24 | 22.19 | 23 | 14484 | 11330 | 50579287 |
Jaw operation | 24.48 | 22.19 | 9 | 14498 | 771 | 50589846 |
Diffuse large B-cell lymphoma recurrent | 24.45 | 22.19 | 11 | 14496 | 1584 | 50589033 |
Toothache | 24.25 | 22.19 | 27 | 14480 | 16867 | 50573750 |
Cardiac cirrhosis | 24.13 | 22.19 | 6 | 14501 | 133 | 50590484 |
Hepatic enzyme increased | 24.10 | 22.19 | 5 | 14502 | 137375 | 50453242 |
Nail avulsion | 23.92 | 22.19 | 6 | 14501 | 138 | 50590479 |
Eosinophil count increased | 23.88 | 22.19 | 20 | 14487 | 8810 | 50581807 |
Scintillating scotoma | 23.63 | 22.19 | 6 | 14501 | 145 | 50590472 |
Anaemia | 23.59 | 22.19 | 138 | 14369 | 252318 | 50338299 |
Body temperature decreased | 23.19 | 22.19 | 26 | 14481 | 16369 | 50574248 |
Postictal state | 22.76 | 22.19 | 9 | 14498 | 941 | 50589676 |
Mediastinal disorder | 22.57 | 22.19 | 7 | 14500 | 356 | 50590261 |
Odynophagia | 22.38 | 22.19 | 17 | 14490 | 6515 | 50584102 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Neutropenia | 105.98 | 25.84 | 100 | 3261 | 131611 | 29439555 |
Febrile neutropenia | 73.00 | 25.84 | 76 | 3285 | 112164 | 29459002 |
Off label use | 68.57 | 25.84 | 122 | 3239 | 300678 | 29270488 |
Malignant neoplasm progression | 59.01 | 25.84 | 56 | 3305 | 73803 | 29497363 |
Febrile bone marrow aplasia | 57.51 | 25.84 | 24 | 3337 | 7327 | 29563839 |
Neutropenic sepsis | 52.67 | 25.84 | 26 | 3335 | 11701 | 29559465 |
Disease progression | 47.03 | 25.84 | 52 | 3309 | 81864 | 29489302 |
Toxic erythema of chemotherapy | 39.72 | 25.84 | 7 | 3354 | 71 | 29571095 |
Myelosuppression | 37.47 | 25.84 | 21 | 3340 | 12206 | 29558960 |
Metastases to lung | 37.01 | 25.84 | 18 | 3343 | 7837 | 29563329 |
Product use in unapproved indication | 34.86 | 25.84 | 46 | 3315 | 86829 | 29484337 |
Neoplasm progression | 34.07 | 25.84 | 23 | 3338 | 18589 | 29552577 |
Leukopenia | 33.30 | 25.84 | 36 | 3325 | 55167 | 29515999 |
Product leakage | 32.97 | 25.84 | 8 | 3353 | 415 | 29570751 |
Interstitial lung disease | 31.98 | 25.84 | 36 | 3325 | 57682 | 29513484 |
Hypophosphataemia | 30.97 | 25.84 | 16 | 3345 | 7908 | 29563258 |
Pneumonitis | 29.75 | 25.84 | 25 | 3336 | 28019 | 29543147 |
Thrombocytopenia | 27.07 | 25.84 | 52 | 3309 | 134771 | 29436395 |
Diffuse large B-cell lymphoma refractory | 26.80 | 25.84 | 8 | 3353 | 914 | 29570252 |
Metastases to the mediastinum | 26.67 | 25.84 | 6 | 3355 | 223 | 29570943 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malignant neoplasm progression | 481.78 | 20.84 | 301 | 13675 | 112570 | 64372186 |
Neutropenia | 331.26 | 20.84 | 328 | 13648 | 239296 | 64245460 |
Disease progression | 269.37 | 20.84 | 232 | 13744 | 141448 | 64343308 |
Metastases to bone | 244.99 | 20.84 | 109 | 13867 | 20326 | 64464430 |
Metastases to lung | 210.90 | 20.84 | 90 | 13886 | 15174 | 64469582 |
Metastases to liver | 207.35 | 20.84 | 102 | 13874 | 23839 | 64460917 |
Neoplasm progression | 194.01 | 20.84 | 117 | 13859 | 40847 | 64443909 |
Palmar-plantar erythrodysaesthesia syndrome | 159.30 | 20.84 | 91 | 13885 | 28728 | 64456028 |
Mucosal inflammation | 144.77 | 20.84 | 115 | 13861 | 62469 | 64422287 |
Neuropathy peripheral | 124.54 | 20.84 | 140 | 13836 | 117385 | 64367371 |
Febrile neutropenia | 123.19 | 20.84 | 176 | 13800 | 187481 | 64297275 |
Metastases to lymph nodes | 119.06 | 20.84 | 51 | 13925 | 8666 | 64476090 |
Breast cancer metastatic | 118.31 | 20.84 | 48 | 13928 | 7121 | 64477635 |
Neutropenic sepsis | 106.34 | 20.84 | 65 | 13911 | 23207 | 64461549 |
Metastases to central nervous system | 99.19 | 20.84 | 52 | 13924 | 13860 | 64470896 |
Breast cancer recurrent | 90.04 | 20.84 | 30 | 13946 | 2553 | 64482203 |
Myelosuppression | 89.99 | 20.84 | 59 | 13917 | 23771 | 64460985 |
Tonsillar disorder | 84.50 | 20.84 | 23 | 13953 | 978 | 64483778 |
PIK3CA-activated mutation | 78.37 | 20.84 | 19 | 13957 | 506 | 64484250 |
Osteonecrosis of jaw | 70.98 | 20.84 | 63 | 13913 | 39762 | 64444994 |
Bone marrow failure | 64.67 | 20.84 | 65 | 13911 | 47887 | 64436869 |
Off label use | 64.43 | 20.84 | 289 | 13687 | 632517 | 63852239 |
Blood uric acid decreased | 64.34 | 20.84 | 19 | 13957 | 1087 | 64483669 |
Haematotoxicity | 64.02 | 20.84 | 38 | 13938 | 12858 | 64471898 |
Febrile bone marrow aplasia | 63.39 | 20.84 | 36 | 13940 | 11219 | 64473537 |
Nasal disorder | 60.57 | 20.84 | 23 | 13953 | 2861 | 64481895 |
Ejection fraction decreased | 60.50 | 20.84 | 50 | 13926 | 28657 | 64456099 |
Eosinophil percentage increased | 59.61 | 20.84 | 19 | 13957 | 1405 | 64483351 |
Thrombocytopenia | 59.37 | 20.84 | 142 | 13834 | 223659 | 64261097 |
Metastases to peritoneum | 55.96 | 20.84 | 23 | 13953 | 3524 | 64481232 |
EGFR gene mutation | 53.45 | 20.84 | 13 | 13963 | 351 | 64484405 |
Fall | 48.60 | 20.84 | 15 | 13961 | 416811 | 64067945 |
Therapy partial responder | 47.76 | 20.84 | 29 | 13947 | 10219 | 64474537 |
Neurotoxicity | 44.20 | 20.84 | 41 | 13935 | 27363 | 64457393 |
Pleural effusion | 43.33 | 20.84 | 89 | 13887 | 126470 | 64358286 |
Peripheral sensory neuropathy | 42.52 | 20.84 | 28 | 13948 | 11350 | 64473406 |
Vessel puncture site bruise | 41.73 | 20.84 | 11 | 13965 | 413 | 64484343 |
Metastases to skin | 39.46 | 20.84 | 14 | 13962 | 1438 | 64483318 |
Metastases to spine | 39.08 | 20.84 | 18 | 13958 | 3625 | 64481131 |
Polyneuropathy | 38.51 | 20.84 | 33 | 13943 | 19861 | 64464895 |
Pancytopenia | 38.02 | 20.84 | 91 | 13885 | 143218 | 64341538 |
Hormone receptor positive breast cancer | 34.92 | 20.84 | 9 | 13967 | 309 | 64484447 |
Hepatotoxicity | 34.61 | 20.84 | 43 | 13933 | 39919 | 64444837 |
Leukopenia | 34.41 | 20.84 | 71 | 13905 | 101171 | 64383585 |
Hyperchlorhydria | 32.99 | 20.84 | 13 | 13963 | 1786 | 64482970 |
Blood creatinine decreased | 32.98 | 20.84 | 20 | 13956 | 7030 | 64477726 |
Injection site extravasation | 32.92 | 20.84 | 21 | 13955 | 8065 | 64476691 |
Lymphangiosis carcinomatosa | 32.83 | 20.84 | 13 | 13963 | 1808 | 64482948 |
Hypothalamo-pituitary disorder | 31.96 | 20.84 | 11 | 13965 | 1033 | 64483723 |
Stomatitis | 31.69 | 20.84 | 72 | 13904 | 109533 | 64375223 |
Pituitary tumour | 31.34 | 20.84 | 11 | 13965 | 1095 | 64483661 |
Agranulocytosis | 31.30 | 20.84 | 40 | 13936 | 38189 | 64446567 |
Disease recurrence | 30.71 | 20.84 | 36 | 13940 | 31474 | 64453282 |
Decreased appetite | 30.36 | 20.84 | 131 | 13845 | 281158 | 64203598 |
Metastases to the mediastinum | 30.30 | 20.84 | 9 | 13967 | 525 | 64484231 |
Nausea | 29.98 | 20.84 | 280 | 13696 | 785520 | 63699236 |
Blood lactate dehydrogenase increased | 29.30 | 20.84 | 36 | 13940 | 33042 | 64451714 |
Transaminases | 28.88 | 20.84 | 6 | 13970 | 77 | 64484679 |
Drug hypersensitivity | 28.70 | 20.84 | 8 | 13968 | 237807 | 64246949 |
Mediastinum neoplasm | 28.14 | 20.84 | 6 | 13970 | 88 | 64484668 |
Primary mediastinal large B-cell lymphoma | 28.07 | 20.84 | 5 | 13971 | 26 | 64484730 |
Constipation | 28.03 | 20.84 | 111 | 13865 | 229226 | 64255530 |
Breast cancer | 27.91 | 20.84 | 33 | 13943 | 29115 | 64455641 |
Gene mutation | 27.83 | 20.84 | 12 | 13964 | 2070 | 64482686 |
Diarrhoea | 27.78 | 20.84 | 258 | 13718 | 722446 | 63762310 |
Toxic erythema of chemotherapy | 27.61 | 20.84 | 7 | 13969 | 225 | 64484531 |
Gingival bleeding | 27.45 | 20.84 | 24 | 13952 | 14830 | 64469926 |
Nail avulsion | 27.42 | 20.84 | 6 | 13970 | 100 | 64484656 |
Lower limb fracture | 27.30 | 20.84 | 23 | 13953 | 13522 | 64471234 |
Gastrointestinal toxicity | 27.24 | 20.84 | 16 | 13960 | 5306 | 64479450 |
Osteonecrosis | 27.09 | 20.84 | 32 | 13944 | 28197 | 64456559 |
Arthralgia | 26.74 | 20.84 | 34 | 13942 | 442226 | 64042530 |
Nail infection | 25.85 | 20.84 | 11 | 13965 | 1836 | 64482920 |
Ascites | 25.33 | 20.84 | 47 | 13929 | 61954 | 64422802 |
Hypertransaminasaemia | 25.19 | 20.84 | 17 | 13959 | 7174 | 64477582 |
Acquired gene mutation | 25.09 | 20.84 | 11 | 13965 | 1975 | 64482781 |
Tumour marker increased | 24.88 | 20.84 | 13 | 13963 | 3437 | 64481319 |
Folate deficiency | 24.58 | 20.84 | 12 | 13964 | 2751 | 64482005 |
Hypotension | 24.39 | 20.84 | 28 | 13948 | 380946 | 64103810 |
Toothache | 24.14 | 20.84 | 24 | 13952 | 17435 | 64467321 |
Scintillating scotoma | 23.34 | 20.84 | 6 | 13970 | 204 | 64484552 |
Jaw operation | 23.24 | 20.84 | 8 | 13968 | 751 | 64484005 |
Cardiac cirrhosis | 23.06 | 20.84 | 6 | 13970 | 214 | 64484542 |
Acute myeloid leukaemia | 22.90 | 20.84 | 29 | 13947 | 27434 | 64457322 |
Product use in unapproved indication | 21.98 | 20.84 | 86 | 13890 | 176532 | 64308224 |
Cardiotoxicity | 21.86 | 20.84 | 18 | 13958 | 10256 | 64474500 |
Metastatic neoplasm | 21.81 | 20.84 | 13 | 13963 | 4429 | 64480327 |
Osteolysis | 21.47 | 20.84 | 11 | 13965 | 2792 | 64481964 |
Joint swelling | 21.31 | 20.84 | 10 | 13966 | 215372 | 64269384 |
Gastric neoplasm | 21.18 | 20.84 | 6 | 13970 | 296 | 64484460 |
Anaemia | 20.91 | 20.84 | 147 | 13829 | 378533 | 64106223 |
None
Source | Code | Description |
---|---|---|
ATC | L01CA04 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS Vinca alkaloids and analogues |
FDA CS | M0022674 | Vinca Alkaloids |
MeSH PA | D050256 | Antimitotic Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D000972 | Antineoplastic Agents, Phytogenic |
MeSH PA | D050257 | Tubulin Modulators |
FDA EPC | N0000175612 | Vinca Alkaloid |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:47868 | photosensitising agent |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Non-small cell lung cancer | indication | 254637007 | DOID:3908 |
Kaposi's sarcoma | off-label use | 109385007 | |
Neoplasm of endometrium | off-label use | 123844007 | DOID:1380 |
Small cell carcinoma of lung | off-label use | 254632001 | DOID:5409 |
Metastatic Breast Carcinoma | off-label use | ||
Disorder of lung | contraindication | 19829001 | DOID:850 |
Infectious disease | contraindication | 40733004 | |
Gastrointestinal perforation | contraindication | 51875005 | |
Hepatic failure | contraindication | 59927004 | |
Interstitial pneumonia | contraindication | 64667001 | |
Intestinal obstruction | contraindication | 81060008 | DOID:8437 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Gastrointestinal obstruction | contraindication | 126765001 | |
Pregnancy, function | contraindication | 289908002 | |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Hepatic Metastases | contraindication | ||
Intestinal Ischemic Necrosis | contraindication | ||
Severe Granulocytopenia | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.32 | acidic |
pKa2 | 13.35 | acidic |
pKa3 | 8.55 | Basic |
pKa4 | 7.39 | Basic |
pKa5 | 6.11 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Tubulin beta | Tumour-associated antigen | INHIBITOR | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
Cytochrome P450 3A4 | Enzyme | IC50 | 6 | DRUG MATRIX | |||||
Substance-K receptor | GPCR | Ki | 6.27 | DRUG MATRIX |
ID | Source |
---|---|
4023981 | VUID |
N0000021986 | NUI |
D01935 | KEGG_DRUG |
125317-39-7 | SECONDARY_CAS_RN |
4020895 | VANDF |
4023981 | VANDF |
C0078257 | UMLSCUI |
CHEBI:480999 | CHEBI |
GDF | PDB_CHEM_ID |
CHEMBL553025 | ChEMBL_ID |
CHEMBL538943 | ChEMBL_ID |
CHEMBL3039595 | ChEMBL_ID |
D000077235 | MESH_DESCRIPTOR_UI |
DB00361 | DRUGBANK_ID |
7105 | IUPHAR_LIGAND_ID |
6054 | INN_ID |
Q6C979R91Y | UNII |
5311497 | PUBCHEM_CID |
114527 | RXNORM |
2135 | MMSL |
46388 | MMSL |
5676 | MMSL |
d03810 | MMSL |
004380 | NDDF |
004381 | NDDF |
108792008 | SNOMEDCT_US |
108794009 | SNOMEDCT_US |
372541004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Vinorelbine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-204 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 27 sections |
Vinorelbine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45963-607 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 19 sections |